The antiandrogen cyproterone acetate induces synthesis of transforming growth factor β1 in the parenchymal cells of the liver accompanied by an enhanced sensitivity to undergo apoptosis and necrosis without inflammation

Hepatology

Volumn 23, Issue 2, 1996, Pages 329-337

  Oberhammer, Franziska ^a,d   Naoy, Peter ^b   Tiefenbacher, Roman ^a   Fröschl, Gertraud ^a   Bouzahzah, Boumediene ^c   Thorgeirsson, Snorri S ^b   Carr, Brian ^c  

^a Institute of Tumor Biology   (Austria)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIANDROGEN; ASPARTATE AMINOTRANSFERASE; CYPROTERONE ACETATE; DNA; GLUTAMATE DEHYDROGENASE; LIVER ENZYME; MESSENGER RNA; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIAGNOSIS; DNA SYNTHESIS; DOSE RESPONSE; ETIOLOGY; FEMALE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRAGASTRIC DRUG ADMINISTRATION; LIVER NECROSIS; LIVER PARENCHYMA; LIVER TUMOR; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RAT;

ANDROGEN ANTAGONISTS; ANIMALS; APOPTOSIS; BODY WEIGHT; CYPROTERONE ACETATE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYMES; FEMALE; HYPERPLASIA; LIVER; NECROSIS; PHAGOCYTOSIS; RATS; RATS, WISTAR; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030067146     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510230220     Document Type: Article

References (25)

1. Neumann F. Pharmacology and potential use of cyproterone acetate. Horm Metab Res 1977;9:1-13.
2. Hammerstein J, Meckies J, Leo-Rossberg I, Moltz L, Zielske F. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem 1975;6:827-836.
3. Holdaway IM, Croxson MS, Ibbertson HK, Sheesan A, Knox B, France J. Cyproterone acetate as initial treatment and maintenance therapy for hirsutism. Acta Endocrinol 1985;109:522-529.
4. Meijers WH, Willemse PHB, Sleijfer DT, Mulder NH, Grond J. Hepatocellular damage by cyproterone acetate. Eur J Cancer Clin Oncol 1986;22:1121-1122.
5. Levesque H, Trivalle G, Manchon ND, Vinel JP, Mooore N, Hemet J, Courtois H, et al. Fulminant hepatitis due to cyproterone acetate. Lancet 1989;8640:215-216.
6. Blake JC, Sawyerr AM, Dooley JS, Scheuer PJ, McIntyre N. Severe hepatitis caused by cyproterone acetate. Gut 1990; 31:556-557.
7. Parys BT, Hamid S, Thomson RGN. Severe hepatocellular dysfunction following cyproterone acetate therapy. Br J Urol 1991;67:312-313.
8. Drakos PE, Gez E, Catane R. Hepatitis due to cyproterone acetate. Eur J Cancer 1992;28A:1931-1932.
9. Dourakis SP, Alexopoulou AA, Hadzyannis SJ. Fulminant hepatitis after flutamide treatment. J Hepatol 1994;20:350-353.
10. Bressolllette L, Dubois A, Carlhant D, Morand C, Mottier D, Riche C. Hepatite Mortelle a l'acetate cyproterone. Therapie 1994;49:153.
11. Hirsch D, Bernheim J, Kovatz S, Shenkman L. Fatal fulminant hepatitis from cyproterone acetate. Israel J Med Sci 1994; 30:238-240.
12. Ohri SK, Caer JAR, Keane PF. Hepatocellular carcinoma and treatment with cyproterone acetate. Br J Urol 1991;67:213-221.
13. Kattan J, Spatz A, Culine S, Terrier Lacombe MJ, Elias D, Droz JP. Hepatocellular carcinoma during hormone therapy for prostate cancer. Am J Clin Oncol Cancer Clin Trials 1994;17:390-392.
14. Watanabe S, Yamasaki S, Tanae A, Hibi I, Honna T. Three cases of hepatocellular carcinoma among cyproterone users. Lancet 1994;344:1567-1568.
15. Rudiger T, Beckmann W, Queisser W. Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinylestradiol. Lancet 1995;345:452-453.
16. Schulte-Hermann R, Hoffman V, Parzefall W, Kallenbach M, Gerhardt A, Schuppler J. Adaptive responses of rat liver to the gestagen and anti-androgen cyproterone acetate and other inducers. II. Induction of growth. Chem Biol Interact 1980;31:287-300.
17. Bursch W, Lauer B, Timmermann-Trosiener I, Barthel G, Schuppler J, Schulte-Hermann R. Controlled cell death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis 1984;5:453-458.
18. Bursch W, Taper H, Lauer B, Schulte-Hermann R. Quantitative histological and histochemical studies on the occurrence and stages of controlled cell death (apoptosis) during regression of rat liver hyperplasia. Virchows Arch 1985;50:153-166.
19. Bursch W, Düsterberg B, Schulte-Hermann R. Growth, regression and cell death in rat liver as related to tissue levels of the hepatomitogen cyproterone acetate. Arch Toxicol 1986;59:221-227.
20. Servais P, Galand P. Apoptosis, cell proliferation and c-ras expression during and after cyproterone acetate (CPA) induced liver hyperplasia. Cell Biol Int Rep 1992;16:319-328.
21. Eagon PK, Elm MS, Stafford EA, Porter LE. Androgen receptor in human liver: characterisation and quantitation in normal and diseased liver. HEPATOLOGY 1994;19:92-100.
22. Mayol X, Neal GE, Davies R, Romero A, Estadella MD, Domingo J. Ethinyl estradiol-induced cell proliferation in rat liver: involvement of specific populations of hepatocytes. Carcinogenesis 1992;13:2381-2388.
23. Bursch W, Oberhammer F, Jirtle RL, Askari M, Sedivy R, Grasl-Kraupp B, Purchio AF. Transforming growth factor β1 as a signal for induction of cell death by apoptosis. Br J Cancer 1993;67:531-536.
24. Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio AF, Bursch W, Schulte-Hermann R. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor-β1. Proc Natl Acad Sci U S A 1992;89:5408-5412.
25. Oberhammer FA, Bursch W, Tiefenbacher R, Fröschl G, Pavelka M, Purchio TF, Schulte-Hermann R. Apoptosis is induced by transforming growth factor-β1 within 5 hours in regressing liver without significant fragmentation of the DNA. HEPATOLOGY 1993;18:1238-1246.